Innate Pharma (OTCMKTS:IPHYF) Trading Down 21.3% - Should You Sell?

Key Points

• Innate Pharma's stock price fell by 21.3%, closing at $1.62 after trading as low as that value during mid-day trading.
• Approximately 125 shares were traded, with the company's 50-day moving average at $1.67 and 200-day moving average at $1.88.
• Innate Pharma is a biotechnology company developing immunotherapies for cancer, with key products in various phases of clinical trials targeting multiple cancer types.

Innate Pharma SA (OTCMKTS:IPHYF - )'s share price dropped 21.3% during mid-day trading on Wednesday . The stock traded as low as $1.62 and last traded at $1.62. Approximately 125 shares were traded during mid-day trading, The stock had previously closed at $2.06.

Innate Pharma Stock Down 21.3%

The firm's 50-day moving average price is $1.67 and its 200-day moving average price is $1.88.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.